Anticoagulation 2017: The key lessons and implications from RE-CIRCUIT / RE-DUAL
Latest frontiers in anticoagulation therapy (1/4)Jan. 12, 2018 - Prof. John Eikelboom, prof. Saskia Middeldorp, Dr. Hanna Pohjantähti-Maaroos
Prof. John Eikelboom summarizes results from RE-CIRCUIT / RE-DUAL PCI trials and discusses the implications for clinical practice.
Video navigation menu
- RE-CIRCUIT: Uninterrupted dabigatran versus warfarin for ablation in AF 01:19
- RE-DUAL PCI: Dual antithrombotic therapy with dabigatran after PCI in AF 03:38
- Should patients on factor Xa inhibitors be switched to dabigatran before catheter ablation? 06:08
- Will RE-DUAL PCI data change clinical practice? 07:57
- How do the RE-DUAL results compare with triple therapy? 09:27
- Can RE-DUAL PCI data also be applied to patients treated with ticagrelor? 10:48
- Do these results apply to patients on hemodialysis? 13:00
This educational video is part of a series called 'Latest frontiers in anticoagulation therapy'.
To review and summarize recent clinical evidence on non-vitamin K antagonist anticoagulants (NOACS) in patients with atrial fibrillation and thrombosis
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Prof. John Eikelboom, Associate Professor in the Department of Medicine at McMaster University, Hamilton, Ontario, Canada
Prof. Saskia Middeldorp, internist, professor of Vascular Medicine at the Academic Medical Center Amsterdam, The Netherlands
Dr. Hanna Pohjantähti-Maaroos, Heart Center, Kuopio University Hospital, Finland
Funding to produce this educational video series was provided by an unrestricted educational grant from Boehringer Ingelheim.